BENTO - Bronchoscopic Lung Volume Reduction in Severe Emphysema Using Thermoablation

Launched by IHF GMBH - INSTITUT FÜR HERZINFARKTFORSCHUNG · Feb 6, 2023

Keywords

ClinConnect Summary

The BENTO trial is studying a new treatment for people with severe emphysema, a serious lung condition that makes it hard to breathe. This trial is comparing a procedure called bronchoscopic lung volume reduction using thermoablation with standard care, which is based on current medical guidelines. The goal is to see if this new treatment can help improve breathing and overall quality of life for patients.

To participate in the trial, you must be between 40 and 75 years old and have been diagnosed with severe emphysema that affects both upper lobes of your lungs. You should also have tried other treatment options without success and need to meet specific health criteria, such as having a certain level of lung function and being a non-smoker for at least six months. If you join the trial, you will receive either the new treatment or the usual care, and your progress will be monitored closely by a team of specialists. This trial might be an opportunity to receive a cutting-edge treatment that could help manage your condition better.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age: ≥ 40 years and ≤ 75 years
• • Written informed consent obtained from the patient
• * Severe emphysema with indication for BTVA:
• • bilateral heterogeneous emphysema of the upper lobes in GOLD stage 3/4.
• • evidence of severe emphysema in high-resolution computed tomography
• • functional evidence of severe pulmonary hyperinflation
• • Collateral ventilation positive
• • FEV1 post lysis between 20% and \< 45% (calculated)
• • Total lung capacity (TLC) ≥ 100% (calculated)
• • Residual volume (RV) \> 175% (calculated)
• • arterial blood gas values of: PaCO2 ≤ 50 mmHg; PaO2 \> 50 mmHg on room air.
• • marked dyspnoea with a score ≥ 2 on the Medical Research Council modified scale (mMRC).
• • 6-minute walk test \> 140 metres
• • Patient-specific, pre-interventional exhaustion of conservative treatment options
• • optimised medical therapy (according to the GOLD guidelines)
• • Non-smoker for 6 months prior to inclusion
• • Evidence of completed pulmonary and geriatric rehabilitation in the last 4 years
• • ≥ 6 weeks outpatient or
• • ≥ 3 weeks inpatient or
• • Participation in regular physical activities that go beyond the activities of daily living (e.g. a walking programme)
• • Mentally and physically able to participate in the study procedures and visits
• • Indication within the framework of an interdisciplinary case conference with specialists in pneumology, radiology and thoracic surgery in accordance with §3 of the guideline on quality assurance measures in accordance with § 136 Paragraph 1 Sentence 1 Number 2 SGB V for inpatient care with bronchoscopic lung volume reduction procedures for severe emphysema (QS-RL BLVR).
• Exclusion Criteria:
• • Any condition that would interfere with the conduct of the clinical trial follow-up or bronchoscopy or affect the outcome of the clinical trial
• • DLCO \< 20% (calculated)
• • Body mass index (BMI) \< 18 kg/m2 or \> 32 kg/m2
• • Pulmonary hypertension
• • Peak systolic PAP \> 45 mmHg or mean PAP \> 25 mmHg
• • Right heart catheter measurements are considered authoritative over echocardiogram measurements
• • Clinically significant bronchiectasis
• • Pneumothorax or pleural effusions within the last 6 months
• • Heart and/or lung transplantation, surgical lung volume reduction (LVRS), bullectomy or thoracic surgery with removal of lung tissue
• • Recent respiratory infection or COPD exacerbation in the last 6 weeks
• * Unstable COPD (any of the following conditions):
• • \>3 COPD-related hospitalisations requiring antibiotics in the last 12 months
• • COPD-related hospital stay in the last 3 months
• • daily use of systemic steroids, \> 5 mg prednisolone
• • Single large bulla (defined as \> 1/3 of the volume of the lobe) in the upper lobe or paraseptal emphysema distribution in the lobe being treated
• • Coagulopathy or current use of anticoagulants
• • Patients with current endobronchial valves or explanted valves in the target lobe with obvious airway obstruction in a segment to be treated with InterVapor®
• • Patients with implanted, endobronchial coils (coils)
• • Patients with previous endobronchial polymer/adhesive treatment
• • Patients with immune system disorders or concomitant diseases that necessitate the use of immunosuppressants of clinical relevance
• * History of any of the following conditions:
• • Myocardial infarction or acute coronary syndrome in the previous year
• • Hospitalisation for left heart failure in the last year
• • clinically leading asthma disease or alpha-1-antitrypsin deficiency
• • Known sensitivity to medications required to perform bronchoscopy
• • Life expectancy \< 12 months
• • Newly prescribed morphine derivatives within the last 4 weeks
• • Pregnancy at the time of inclusion